Printer Friendly

CYGNUS FILES IND FOR SECOND-GENERATION NICOTINE PATCHES

 REDWOOD CITY, Calif., July 28 /PRNewswire/ -- Cygnus Therapeutic Systems (NASDAQ: CYGN), a transdermal drug delivery company, announced that it has filed an Investigational New Drug (IND) registration with the U.S. Food and Drug Administration (FDA) for a new family of nicotine transdermal systems designed to meet the smoking cessation needs of more dependent smokers. The patches in this family are in multiple-dosage strengths, including strengths greater than available in current patches. Cygnus believes that a patient's probability of success at smoking cessation will be enhanced if the nicotine replacement regimen is matched with the patient's smoking pattern. Cygnus' business strategy is to retain control of projects further into the development process in order to accelerate the time to market and to capture a greater percentage of the economic value once these products are commercialized. Accordingly, Cygnus will be filing this IND and conducting its own clinical trials without the participation of a pharmaceutical partner.
 Cygnus designed, developed and manufactures Nicotrol(R), nicotine transdermal system which delivers nicotine during waking hours. Although controlled scientific studies comparing Nicotrol to competing products have not yet been performed, the company believes that nicotine delivery during waking hours avoids the potential side effects of insomnia, nightmares and headaches associated with 24-hour delivery. Nicotrol was launched in 1992 and is marketed by Parke-Davis, a division of Warner-Lambert.
 Cygnus is a leader in the development of advanced transdermal drug delivery systems. The company's primary focus is on developing products for the smoking cessation, hormone replacement, glucose monitoring and consumer products markets. Cygnus has two products in Phase III clinical trials: a seven-day estradiol transdermal system for the treatment of menopausal symptoms, and a fentanyl patch for moderate to severe post-operative pain management. The company has more than a dozen other products in various stages of development. These products include six transdermal products that address the hormone replacement therapy market, a portfolio of second-generation nicotine replacement products and two consumer products.
 -0- 7/28/93
 /CONTACT: Craig Carlson of Cygnus, 415-369-4300/
 (CYGN)


CO: Cygnus Therapeutic Systems; U.S. Food and Drug Administration ST: California IN: MTC SU:

GT-TB -- SJ007 -- 6806 07/28/93 14:28 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 28, 1993
Words:359
Previous Article:BECHTEL AWARDED PROJECT SERVICES CONTRACT TO HELP DEVELOP GIANT OIL FIELDS IN KAZAKHSTAN
Next Article:QUADRA LOGIC TECHNOLOGIES INC. COMPLETES CDN $21.2 MILLION STOCK OFFERING
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters